Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 7/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.49 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.43 |
| ▸ | XDH | P47989 | 2/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22618859 | 0.87 | ACACB (0.47) | ACACBROCK2ROCK1MMENOS2 | |
| SCHEMBL34468847 | 0.84 | ACACB (0.52) | ACACBROCK2ROCK1MMENOS2 | |
| SCHEMBL28210633 | 0.83 | ACACB (0.45) | ACACBROCK2MLYCDROCK1MME | |
| SCHEMBL566140 | 0.82 | ACACB (0.43) | ACACBROCK2ROCK1MME | |
| SCHEMBL872179 | 0.79 | — | — | |
| SCHEMBL26763905 | 0.78 | GAA (0.53) | ACACBROCK2MLYCDROCK1NOS2 | |
| SCHEMBL15087996 | 0.78 | SMN1; SMN2 (0.62) | ACACBROCK2ROCK1ACACA | |
| SCHEMBL8019241 | 0.78 | NOS2 (0.43) | ACACBROCK2ROCK1MMENOS2 | |
| Isopropyl Alcohol SCHEMBL7083853 | 0.77 | ROCK2 (0.41) | ACACBROCK2ROCK1XDHNOS2 | |
| SCHEMBL3180341 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137329-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC (US) | 2025-06-26 | — | — | WO | claimed |
| EP-4240738-B1 | PYRAZOLE DERIVATIVES AS RET KINASE INHIBITORS | LILLY CO ELI (US) | 2025-05-07 | — | — | EP | disclosed |
| US-10703754-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | ELI LILLY AND COMPANY (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190194202-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELI LILLY AND COMPANY | 2019-06-27 | — | — | US | disclosed |
| US-20180265511-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELI LILLY AND COMPANY | 2018-09-20 | — | — | US | disclosed |
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2018-05-17 | — | — | US | disclosed |
| US-20180111956-A1 | SYNTHESIS OF DESOSAMINES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-04-26 | — | — | US | disclosed |
| US-9920053-B2 | N-(hetero)aryl-substituted heteroyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system | CHRONOS THERAPEUTICS LIMITED (GB) | 2018-03-20 | — | — | US | disclosed |
| US-20170253592-A1 | N-(HETERO)ARYL-SUBSTITUTED HETEROYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM | SHIRE INTERNATIONAL GMBH (CH) | 2017-09-07 | — | — | US | disclosed |
| US-20130059869-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | HYDRA BIOSCIENCES, INC. | 2013-03-07 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120046305-A1 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS | ELI LILLY AND COMPANY | 2012-02-23 | — | — | US | disclosed |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703754-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | ELANE, CASP3, MMP8 | ACACB 1397/4885ROCK2 2574/4885MLYCD 4730/4885 |
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | ACACB 772/4885ROCK2 3372/4885MLYCD 2512/4885 |
| US-20180265511-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | ACACB 1397/4885ROCK2 2574/4885MLYCD 4730/4885 |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | ACACB 772/4885ROCK2 3372/4885MLYCD 2512/4885 |
| US-20120046305-A1 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS | TRPA1, TRPV1, TRPV3 | ACACB 1535/4885ROCK2 3833/4885MLYCD 1327/4885 |
| US-20180111956-A1 | SYNTHESIS OF DESOSAMINES | NANS, GALE, FUT6 | ACACB 723/4885ROCK2 3617/4885MLYCD 206/4885 |
| US-20170253592-A1 | N-(HETERO)ARYL-SUBSTITUTED HETEROYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM | SLC6A3, SLC6A2, SLC6A19 | ACACB 2197/4885ROCK2 3638/4885MLYCD 450/4885 |
| US-20190194202-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | ACACB 1397/4885ROCK2 2574/4885MLYCD 4730/4885 |
| US-20130059869-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | ACACB 772/4885ROCK2 3372/4885MLYCD 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.